Deuterated dextromethorphan/quinidine for agitation in Alzheimer's disease

被引：0
|
作者：
Rita Khoury
机构：
[1] Department of Psychiatry and Clinical Psychology
[2] Saint George Hospital University Medical Center-Beirut
[3] Adjunct Faculty, Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine
来源：
Neural Regeneration Research | 2022年 / 05期
关键词：
D O I：
暂无
中图分类号：
R749.16 [];
学科分类号：
100203 ;
摘要：
Alzheimer’s disease(AD) is the most common type of neurode generative disorder; it affects around 47 million individuals worldwide(Prince et al., 2013). AD rose from the 12 th most burdensome disease in the United States in 1990 to the sixth in 2016 in terms of disability-adjusted life years(Alzheimer ’s Disease,
引用
收藏
页码：1013 / 1014
页数：2
相关论文
共 50 条
  • [1] Deuterated dextromethorphan/quinidine for agitation in Alzheimer's disease
    Khoury, Rita
    [J]. NEURAL REGENERATION RESEARCH, 2022, 17 (05) : 1013 - 1014
  • [2] Dextromethorphan-Quinidine for Agitation in Alzheimer Disease RESPONSE
    Newman, John C.
    Steinman, Michael A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (11): : 1166 - 1166
  • [3] Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia
    Ballard, Clive
    Sharp, Samantha
    Corbett, Anne
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (12): : 1233 - 1235
  • [4] Dextromethorphan-Quinidine for Agitation in Alzheimer Disease (vol 315, pg 1166, 2016)
    Cummings, J. L.
    Siffert, J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (15): : 1661 - 1661
  • [5] Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia A Randomized Clinical Trial
    Cummings, Jeffrey L.
    Lyketsos, Constantine G.
    Peskind, Elaine R.
    Porsteinsson, Anton P.
    Mintzer, Jacobo E.
    Scharre, DouglasW.
    De La Gandara, Jose E.
    Agronin, Marc
    Davis, Charles S.
    Uyen Nguyen
    Shin, Paul
    Tariot, Pierre N.
    Siffert, Joao
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (12): : 1242 - 1254
  • [6] NPI Agitation/Aggression Domain Scores Demonstrate Clinically Meaningful Changes in a Phase 2 Study of Dextromethorphan/Quinidine (DM/Q) in Patients with Agitation in Alzheimer's Disease
    Dube, Sanjay
    Cummings, Jeffrey
    Cui, Harry
    Siffert, Joao
    [J]. NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S197 - S198
  • [7] Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia
    Tampi, Rajesh R.
    Joshi, Pallavi
    Marpuri, Padmapriya
    Tampi, Deena J.
    [J]. WORLD JOURNAL OF PSYCHIATRY, 2020, 10 (04): : 29 - 33
  • [8] Dextromethorphan/quinidine (AVP-923) Efficacy and Safety for Treatment of Agitation in Persons with Alzheimer's Disease: Results from a Phase 2 Study (NCT01584440)
    Cummings, Jeffrey
    Lyketsos, Constantine G.
    Tariot, Pierre
    Peskind, Elaine
    Nguyen, Uyen
    Knowles, Nadine
    Shin, Paul
    Siffert, Joao
    [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2015, 23 (03): : S164 - S165
  • [9] Dextromethorphan/Quinidine (AVP-923) Efficacy and Safety for Treatment of Agitation in Persons With Alzheimer's Disease: Results From a Phase 2 Study (NCT01584440)
    Cummins, J.
    Lyketsos, C.
    Tariot, P. N.
    Peskind, E. R.
    Nguyen, U.
    Knowles, N.
    Shin, P.
    Siffert, J.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2015, 63 : S32 - S32
  • [10] Dextromethorphan/Quinidine (AVP-923) Efficacy and Safety for Treatment of Agitation in Alzheimer's Disease (AD): Results from a Phase 2 Study (NCT01584440)
    Cummings, Jeffrey
    Lyketsos, Constantine
    Tariot, Pierre
    Peskind, Elaine
    Uyen Nguyen
    Knowles, Nadine
    Shin, Paul
    Siffert, Joao
    [J]. ANNALS OF NEUROLOGY, 2014, 76 : S100 - S101
12345